In humans, apolipoprotein E (apoE) has 3 isoforms: apoE2, apoE3, and apoE4. APOE4 is a major genetic risk factor for Alzheimer disease (AD).
MMP-9 levels in the CSF of cognitively normal individuals with different APOE genotypes to determine whether apoE4-dependent changes in BBB permeability and CypA-MMP-9 pathway as shown in APOE4, but not APOE3 and APOE2 transgenic mice, also occur in humans.
Methods | Participants were volunteers who were recruited through advertisements or from the Memory Education and Research Initiative Program at the Nathan S. Kline Institute for Psychiatric Research. 9 Participants gave their informed consent to participate in studies approved by the institutional review board of the Nathan S. Kline Institute for Psychiatric Research and New York University School of Medicine. We studied a total of 49 cognitively normal individuals as indicated by the Clinical Dementia Rating score of 0 and Mini-Mental State Examination score of approximately 30. This study did not exclude participants meeting criteria for major depressive disorder because there were no differences in the studied markers of BBB damage in this group compared with controls. The studied individuals represented 3 different APOE genotypes: APOE2/E3 (n = 11), APOE3/E3 (n = 28) and APOE3/E4 (n = 10). Within each genotype, individuals were stratified into 2 age groups-40 through 65 years old and 66 through 85 years old-to control for age-dependent effects (Table) . Cerebrospinal fluid and plasma collection and APOE genotyping were performed as described. 9 Enzyme-linked immunosorbent assays were used to determine levels of CypA (catalog no. sE90979Hu; USCN Life Science), active MMP-9 (catalog no. 72017; AnaSpec), and albumin (catalog no. E-80AL; Immunology Consultant Laboratories). Data were analyzed by multifactorial analysis of variance with 2 factors (age and APOE genotype), with Bonferroni post hoc tests to adjust for multiple comparisons, and Pearson correlation analysis using Graphpad Prism version 5.0. Analyses were performed by an investigator blinded to the experimental conditions. A P value of less than .05 was considered statistically significant.
Results | Older cognitively normal individuals carrying 1 APOE4 allele compared with younger cognitively normal APOE4 carriers or age-matched APOE4 noncarriers had increased Q Alb by approximately 77% and 67%, respectively (P < .01; Figure, A (P < .01; Figure, B ) and active MMP-9 by 167% and 110%, respectively (P < .05; Figure, 
C). No age-dependent changes in
CypA or MMP-9 CSF levels were associated with APOE2 or APOE3 alleles. Importantly, increases in Q Alb values correlated positively with both CypA and active MMP-9 CSF levels in all studied individuals (r = 0.37, P < .01; and r = 0.45, P < .01, respectively) ( Figure, D and E) , indicating the greater the increase in CypA and active MMP-9 levels, the greater the magnitude of BBB breakdown assayed by Q Alb .
Discussion | This study showed that APOE4 carriers may be susceptible to an age-dependent BBB breakdown prior to onset of clinical decline as determined by Clinical Dementia Rating and Mini-Mental State Examination scores. Furthermore, these findings are consistent with experimental studies suggesting that apoE4 leads to BBB damage in transgenic mice via activation of the CypA-MMP-9 pathway. 7 These findings warrant future longitudinal studies to investigate Q Alb and CSF levels of CypA and active MMP-9 in cognitively normal APOE4 carriers as they progress to mild cognitive impairment and eventually AD. With current diagnostic markers, by the time the earliest detectable clinical signs of disease appear, significant brain injury has likely already occurred. Therefore, studying markers of BBB damage along with commonly used β-amyloid 42 and tau CSF levels may contribute to early detection of vascular dysfunction of those at risk for cognitive decline and AD. 
